JP2007520566A5 - - Google Patents

Download PDF

Info

Publication number
JP2007520566A5
JP2007520566A5 JP2006552302A JP2006552302A JP2007520566A5 JP 2007520566 A5 JP2007520566 A5 JP 2007520566A5 JP 2006552302 A JP2006552302 A JP 2006552302A JP 2006552302 A JP2006552302 A JP 2006552302A JP 2007520566 A5 JP2007520566 A5 JP 2007520566A5
Authority
JP
Japan
Prior art keywords
autoantigen
antibody
pharmaceutical composition
antigen
kit
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006552302A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007520566A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2005/003712 external-priority patent/WO2005076965A2/en
Publication of JP2007520566A publication Critical patent/JP2007520566A/ja
Publication of JP2007520566A5 publication Critical patent/JP2007520566A5/ja
Pending legal-status Critical Current

Links

JP2006552302A 2004-02-04 2005-02-04 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法 Pending JP2007520566A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54195904P 2004-02-04 2004-02-04
PCT/US2005/003712 WO2005076965A2 (en) 2004-02-04 2005-02-04 Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity

Publications (2)

Publication Number Publication Date
JP2007520566A JP2007520566A (ja) 2007-07-26
JP2007520566A5 true JP2007520566A5 (enExample) 2008-03-27

Family

ID=34860238

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006552302A Pending JP2007520566A (ja) 2004-02-04 2005-02-04 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法

Country Status (7)

Country Link
US (1) US20070190045A1 (enExample)
EP (1) EP1725254A4 (enExample)
JP (1) JP2007520566A (enExample)
AU (1) AU2005213449A1 (enExample)
CA (1) CA2554978A1 (enExample)
IL (1) IL177193A0 (enExample)
WO (1) WO2005076965A2 (enExample)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030108548A1 (en) * 1993-06-01 2003-06-12 Bluestone Jeffrey A. Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
AU2003300681A1 (en) * 2002-10-02 2004-05-04 Diamyd Medical Ab Formulation of glutarmic acid decarboxylase (gad65) and serum albumin
ES2526343T3 (es) * 2004-06-03 2015-01-09 Novimmune Sa Anticuerpos anti-CD3 y métodos de uso de los mismos
BRPI0607117A2 (pt) * 2005-02-04 2009-08-11 Dow Agrosciences Llc tratamento com anticélulas t e auto-antìgeno de doença auto-imune
SG163615A1 (en) * 2005-07-11 2010-08-30 Macrogenics Inc Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity
US20100209437A1 (en) * 2005-09-12 2010-08-19 Greg Elson Anti-CD3 Antibody Fromulations
ES2405552T3 (es) 2005-11-29 2013-05-31 Actogenix N.V. Inducción de tolerancia mucosa a antiantígenos de células beta de islotes pancreáticos
WO2007084775A2 (en) * 2006-01-20 2007-07-26 The Trustees Of The University Of Pennsylvania Compositions and methods for modulation of suppressor t cell activation
JP2009539841A (ja) * 2006-06-06 2009-11-19 トラークス，インコーポレイテッド 自己免疫疾患の治療における抗ｃｄ３抗体の投与
EP2037961B1 (en) * 2006-06-14 2015-11-11 MacroGenics, Inc. Methods for the treatment of autoimmune disorders using monoclonal antibodies with reduced toxicity
BRPI0721062A2 (pt) * 2006-12-21 2019-09-24 Macrogenics Inc métodos para prevenir ou retardar o início e para prevenir a progressão de diabete autoimune latente, métodos para tratamento de diabete autoimune latente em adultos e para tratar ou prevenir diabete de tipo 1 de início na idade adulta ou para melhorar seus sintomas em um paciente sofrendo do mesmo, e, método para prevenir ou retardar requisição de insulina em um paciente.
DE102007001370A1 (de) * 2007-01-09 2008-07-10 Curevac Gmbh RNA-kodierte Antikörper
EP2774621B1 (en) 2007-01-25 2018-01-24 Intrexon Actobiotics NV Treatment of immune disease by mucosal delivery of antigens
US20090092637A1 (en) * 2007-04-24 2009-04-09 Diamyd Therapeutics Ab Medicaments and methods to treat autoimmune disease and cancer
CA2778334A1 (en) * 2009-10-20 2011-04-28 Charlotte Mckee Anti-cd3 antibody dosing in autoimmune disease
EP2525825A1 (en) * 2010-01-20 2012-11-28 Bayhill Therapeutics, Inc. Combination therapy to treat autoimmune diseases
US9018006B2 (en) 2010-07-23 2015-04-28 The University Of Toledo Stable Tregs and related materials and methods
CN106668852B (zh) * 2012-04-13 2020-12-25 艾棣维欣(苏州)生物制药有限公司 一种治疗和/或预防ⅰ型糖尿病的组合物及其应用
US8735359B2 (en) * 2012-05-24 2014-05-27 Orban Biotech Llc Combinations of modalities for the treatment of diabetes
US20170196949A1 (en) * 2014-06-04 2017-07-13 Diamyd Medical Ab Novel combinations for antigen based therapy
GB201510056D0 (en) * 2015-06-10 2015-07-22 King S College London Multi-peptide composition
EP3551047A1 (en) 2016-12-07 2019-10-16 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
US20210138213A1 (en) 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
AU2018315052B2 (en) * 2017-08-07 2025-01-02 St Vincent's Institute Of Medical Research Type 1 diabetes therapy
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
WO2019246317A1 (en) 2018-06-20 2019-12-26 Progenity, Inc. Treatment of a disease or condition in a tissue originating from the endoderm
CN116726362A (zh) 2018-11-19 2023-09-12 比奥拉治疗股份有限公司 用生物治疗剂治疗疾病的方法和装置
KR102503349B1 (ko) 2019-05-14 2023-02-23 프로벤션 바이오, 인코포레이티드 제1형 당뇨병을 예방하기 위한 방법 및 조성물
CN115666704B (zh) 2019-12-13 2025-09-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
US12122850B2 (en) 2022-03-14 2024-10-22 LamKap Bio gamma AG Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2546544B2 (ja) * 1989-10-27 1996-10-23 アーチ ディベラップメント コーポレイション 免疫強化を促進するための方法と組成物
US6406696B1 (en) * 1989-10-27 2002-06-18 Tolerance Therapeutics, Inc. Methods of stimulating the immune system with anti-CD3 antibodies
US6150584A (en) * 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5885573A (en) * 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6491916B1 (en) * 1994-06-01 2002-12-10 Tolerance Therapeutics, Inc. Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies
FR2730411B1 (fr) * 1995-02-14 1997-03-28 Centre Nat Rech Scient Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes
US5834597A (en) * 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6420140B1 (en) * 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
US6884785B2 (en) * 1999-06-17 2005-04-26 The Scripps Research Institute Compositions and methods for the treatment or prevention of autoimmune diabetes
WO2003028441A1 (en) * 2001-10-02 2003-04-10 The Board Of Trustees Of The Leland Stanford Junior University Gene therapy for the prevention of autoimmune disease
US20040037826A1 (en) * 2002-06-14 2004-02-26 Michelsen Birgitte Koch Combined use of a modulator of CD3 and a GLP-1 compound

Similar Documents

Publication Publication Date Title
JP2007520566A5 (enExample)
JP2005518433A5 (enExample)
JP2007527914A5 (enExample)
AR057807A1 (es) Formulaciones de anticuerpo anti-cd3
IL198870A0 (en) ANTIBODIES THAT BIND TO HUMAN PDGFRa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
EA201390450A1 (ru) Полипептиды с увеличенной продолжительностью действия
IL197831A (en) Human antibodies that bind 4cxcr, preparations containing them and their uses
HRP20192295T1 (hr) Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi)
JP2009521520A5 (enExample)
JP2007522094A5 (enExample)
JP2007509067A5 (enExample)
JP2012509886A5 (enExample)
NO20083785L (no) Funksjonelle antistoffer
AR074777A1 (es) Proteinas de union a antigeno
IL178838A (en) Antibodies that specifically bind to human p-psgl-1 and p-selectin, pharmacological preparations containing such antibody, and momentary acids and their encoded vectors
JP2009505678A5 (enExample)
IL209499A (en) Human monoclonal antibody against influenza virus a, Pharmaceutical preparations containing it and its use in drug preparation
JP2007517055A5 (enExample)
WO2009114040A3 (en) Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
JP2011219478A5 (enExample)
WO2018116267A3 (en) Methods of treatment with anti-factor xi/xia antibodies
JP2011528897A5 (enExample)
IL179240A (en) Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody
EA201290671A1 (ru) Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р
MA37645B1 (fr) Formulations stabilisées contenant des anticorps anti-dll4